PainReform Ltd. (PRFX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRFX Stock Price Chart Interactive Chart >
PRFX Price/Volume Stats
| Current price | $2.82 | 52-week high | $7.85 |
| Prev. close | $2.83 | 52-week low | $2.18 |
| Day low | $2.80 | Volume | 98,400 |
| Day high | $2.94 | Avg. volume | 232,912 |
| 50-day MA | $3.16 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 28.37M |
PainReform Ltd. (PRFX) Company Bio
PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.
Latest PRFX News From Around the Web
Below are the latest news stories about Painreform Ltd that investors may wish to consider to help them evaluate PRFX as an investment opportunity.
We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
PainReform Provides Business Update for the First Quarter of 2021Reports continued progress towards start of Phase 3 trialsHERZLIYA, Israel, May 13, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2021. The Company also announces it has finalized the protocol for its Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery for submission to the regulatory authorities. Ilan Hadar, Chief Executive Officer of PainReform, commented, "We continue to make progress towards commencing our Phase 3 clinical trials of PRF-110. Towards this end, we have been manufacturing clinical trial batches of PRF-110 i... |
PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual ConferenceHERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, CEO of PainReform, has been invited to present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The presentation will be available to all registered participants of the conference on March 17th - 19th and will be posted on PainReform’s website after March 19th. About PainReform PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting... |
PainReform Announces $6.0 Million Private PlacementHERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $6.0 million through the private placement of 1,304,346 ordinary shares and accompanying warrants to purchase an aggregate of up to 652,173 ordinary shares at a combined purchase price of $4.60 per share and accompanying warrant. The warrants will be exercisable immediately at an exercise price of $4.60 per share and will expire five and a half years from the date of issuance. The closing of the private placement is expected to occur on... |
PainReform to Present at the H.C. Wainwright BioConnect 2021 ConferenceHERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.A webcast of PainReform's presentation will be available on-demand as of 6:00 a.m. ET, Monday, January 11, 2021 and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of PainReform's website at www.painreform.com/investors-information/.About PainReformPainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110... |
PRFX Price Returns
| 1-mo | 8.46% |
| 3-mo | -45.66% |
| 6-mo | -36.91% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -36.91% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...